Erratum: Type 2 diabetes (The Lancet (2017) 389(10085) (2239–2251) (S0140673617300582) (10.1016/S0140-6736(17)30058-2));Type 2 diabetes

The Lancet

Volumn 389, Issue 10085, 2017, Pages 2239-2251

  Chatterjee, Sudesna ^a   Khunti, Kamlesh ^a   Davies, Melanie J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALOGLIPTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT;

BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR DISEASE; DIABETIC COMPLICATION; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LOW CALORY DIET; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT CARE; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; TREATMENT INDICATION; COMPLICATION; GLUCOSE BLOOD LEVEL; HEALTH PROMOTION; MASS SCREENING; METABOLISM; PROCEDURES;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; HEALTH PROMOTION; HUMANS; HYPOGLYCEMIC AGENTS; MASS SCREENING; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85012877086     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30539-1     Document Type: Erratum

References (151)

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet 387 (2016), 1513–1530.
2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
3. Seuring, T, Archangelidi, O, Suhrcke, M, The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 33 (2015), 811–831.
4. WHO. Non-communicable diseases country profile 2014. http://www.who.int/nmh/publications/ncd-profiles-2014/en/, July, 2014 (accessed Oct 6, 2016).
5. Gaede, P, Vedel, P, Larsen, N, Jensen, GV, Parving, HH, Pedersen, O, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
7. ADVANCE Collaborative Group, Patel, A, MacMahon, S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
8. Duckworth, W, Abraira, C, Moritz, T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
9. Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
10. Holman, RR, Sourij, H, Califf, RM, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
11. Skyler, JS, Bergenstal, R, Bonow, RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009), 187–192.
12. Cefalu, WT, Glycemic targets and cardiovascular disease. N Engl J Med 358 (2008), 2633–2635.
13. Elwen, FR, Huskinson, A, Clapham, L, et al. An observational study of patient characteristics and mortality following hypoglycemia in the community. BMJ Open Diabetes Res Care, 3, 2015, e000094.
14. Tricco, AC, Ivers, NM, Grimshaw, JM, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 379 (2012), 2252–2261.
15. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. http://www.diabetesatlas.org/, 2015 (accessed Oct 6, 2016).
16. Knowler, WC, Barrett-Connor, E, Fowler, SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
17. Tancredi, M, Rosengren, A, Svensson, AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 373 (2015), 1720–1732.
18. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
19. Harris, MI, Klein, R, Welborn, TA, Knuiman, MW, Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15 (1992), 815–819.
20. Grarup, N, Sandholt, CH, Hansen, T, Pedersen, O, Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond. Diabetologia 57 (2014), 1528–1541.
21. Jenkinson, CP, Goring, HH, Arya, R, Blangero, J, Duggirala, R, DeFronzo, RA, Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype. Genom Data 8 (2015), 25–36.
22. Leong, A, Porneala, B, Dupuis, J, Florez, JC, Meigs, JB, Type 2 diabetes genetic predisposition, obesity, all-cause mortality risk in the US: a multiethnic analysis. Diabetes Care 39 (2016), 539–546.
23. Oram, RA, Patel, K, Hill, A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39 (2016), 337–344.
24. Constantino, MI, Molyneaux, L, Limacher-Gisler, F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 36 (2013), 3863–3869.
25. Wong, ND, Zhao, Y, Patel, R, et al. Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care 39 (2016), 668–676.
26. TODAY Study Group, Zeitler, P, Hirst, K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366 (2012), 2247–2256.
27. Defronzo, RA, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
28. Schwartz, SS, Epstein, S, Corkey, BE, Grant, SF, Gavin, JR 3rd, Aguilar, RB, The time is right for a new classification system for diabetes: rationale and implications of the β-Cell-Centric Classification Schema. Diabetes Care 39 (2016), 179–186.
29. Gruber, K, Moving towards a more precise treatment of diabetes. Lancet Diabetes Endocrinol, 3, 2015, 171.
30. de Jager, J, Kooy, A, Schalkwijk, C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 275 (2014), 59–70.
31. Ceriello, A, Esposito, K, Testa, R, Bonfigli, AR, Marra, M, Giugliano, D, The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care 34 (2011), 697–702.
32. Wilding, JP, The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63 (2014), 1228–1237.
33. Orozco, LJ, Buchleitner, AM, Gimenez-Perez, G, Roque I Figuls, M, Richter, B, Mauricio, D, Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev, 3, 2008 CD003054.
34. Merlotti, C, Morabito, A, Pontiroli, AE, Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab 16 (2014), 719–727.
35. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3 (2015), 866–875.
36. Perreault, L, Temprosa, M, Mather, KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care 37 (2014), 2622–2631.
37. Cardona-Morrell, M, Rychetnik, L, Morrell, SL, Espinel, PT, Bauman, A, Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health, 10, 2010, 653.
38. Dunkley, AJ, Bodicoat, DH, Greaves, CJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 37 (2014), 922–933.
39. Maruthappu, M, Sood, H, Keogh, B, Radically upgrading diabetes prevention in England. Lancet Diabetes Endocrinol 3 (2015), 312–313.
40. Webb, DR, Gray, LJ, Khunti, K, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 54 (2011), 2237–2246.
41. Simmons, RK, Echouffo-Tcheugui, JB, Sharp, SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380 (2012), 1741–1748.
42. Khunti, K, Mani, H, Achana, F, Cooper, N, Gray, LJ, Davies, MJ, Systematic review and meta-analysis of response rates and diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. PLoS One, 10, 2015, e0135702.
43. Colagiuri, S, Lee, CM, Wong, TY, Balkau, B, Shaw, JE, Borch-Johnsen, K, DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 34 (2011), 145–150.
44. Welsh, KJ, Kirkman, MS, Sacks, DB, Role of glycated proteins in the diagnosis and management of diabetes: research gaps and future directions. Diabetes Care 39 (2016), 1299–1306.
45. Thanabalasingham, G, Pal, A, Selwood, MP, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 35 (2012), 1206–1212.
46. Norris, SL, Zhang, X, Avenell, A, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev, 2, 2005 CD004095.
47. Thomas, DE, Elliott, EJ, Naughton, GA, Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev, 3, 2006 CD002968.
48. Davies, MJ, Heller, S, Skinner, TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 336 (2008), 491–495.
49. Khunti, K, Gray, LJ, Skinner, T, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ, 344, 2012, e2333.
50. Belalcazar, LM, Reboussin, DM, Haffner, SM, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 33 (2010), 2297–2303.
51. Look AHEAD Research Group, Wing, RR, Bolin, P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
52. Wing, RR, Bond, DS, Gendrano, IN 3rd, et al. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diabetes Care 36 (2013), 2937–2944.
53. Rubin, RR, Wadden, TA, Bahnson, JL, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care 37 (2014), 1544–1553.
54. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2 (2014), 801–809.
55. Stamler, J, Vaccaro, O, Neaton, JD, Wentworth, D, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993), 434–444.
56. Fox, CS, Golden, SH, Anderson, C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38 (2015), 1777–1803.
57. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
58. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, HC, Miller, ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
59. Gaede, P, Vedel, P, Parving, HH, Pedersen, O, Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999), 617–622.
60. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 74, 2015, 1094.
61. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
62. Control Group, Turnbull, FM, Abraira, C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
63. Ray, KK, Seshasai, SR, Wijesuriya, S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
64. Riddle, MC, Ambrosius, WT, Brillon, DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3·4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33 (2010), 983–990.
65. Wong, MG, Perkovic, V, Chalmers, J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
66. Nissen, SE, Wolski, K, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
67. Scirica, BM, Bhatt, DL, Braunwald, E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
68. White, WB, Cannon, CP, Heller, SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
69. US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication—risk of heart failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm, April 19, 2016 (accessed Oct 6, 2016).
70. Green, JB, Bethel, MA, Armstrong, PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
71. Sarafidis, PA, Tsapas, A, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 374, 2016, 1092.
72. AstraZeneca. Multicenter trial to investigate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534, 2015 (accessed Oct 21, 2015).
73. Janssen Research and Development LLC. CANVAS—CANagliflozin cardioVascular Assessment Study. https://clinicaltrials.gov/ct2/show/NCT01032629, 2015 (accessed Oct 21, 2015).
74. Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016, 10.1056/NEJMoa1607141 published online Sept 15.
75. Pfeffer MA, on behalf of ELIXA steering group. The evaluation of lixisenatide in acute coronary syndrome—the results of ELIXA. ADA Scientific Sessions 2015; Abstracts: 3-CT-SY28.
76. Udell, JA, Cavender, MA, Bhatt, DL, Chatterjee, S, Farkouh, ME, Scirica, BM, Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015), 356–366.
77. Bray, GA, Fruhbeck, G, Ryan, DH, Wilding, JP, Management of obesity. Lancet 387 (2016), 1947–1956.
78. Davies, MJ, Bergenstal, R, Bode, B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA 314 (2015), 687–699.
79. Wadden, TA, Hollander, P, Klein, S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 37 (2013), 1443–1451.
80. Steven, S, Hollingsworth, KG, Al-Mrabeh, A, et al. Very-low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiologic changes in responders and nonresponders. Diabetes Care 39 (2016), 808–815.
81. Mingrone, G, Panunzi, S, De Gaetano, A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
82. DeFronzo, RA, Buse, JB, Kim, T, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59 (2016), 1645–1654.
83. Pernicova, I, Korbonits, M, Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10 (2014), 143–156.
84. Salpeter, SR, Greyber, E, Pasternak, GA, Salpeter, EE, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 4, 2010 CD002967.
85. Inzucchi, SE, Lipska, KJ, Mayo, H, Bailey, CJ, McGuire, DK, Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312 (2014), 2668–2675.
86. Hemmingsen, B, Schroll, JB, Wetterslev, J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2 (2014), E162–E175.
87. Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55 (2012), 1577–1596.
88. Monami, M, Dicembrini, I, Kundisova, L, Zannoni, S, Nreu, B, Mannucci, E, A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 16 (2014), 833–840.
89. Abdelmoneim, AS, Eurich, DT, Light, PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
90. Kahn, SE, Lachin, JM, Zinman, B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 60 (2011), 1552–1560.
91. Nathan, DM, Buse, JB, Kahn, SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36 (2013), 2254–2261.
92. Fuhlendorff, J, Rorsman, P, Kofod, H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47 (1998), 345–351.
93. Miwa, S, Watada, H, Ohmura, C, Tanaka, Y, Kawamori, R, Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J 51 (2004), 393–398.
94. Black, C, Donnelly, P, McIntyre, L, Royle, PL, Shepherd, JP, Thomas, S, Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2, 2007 CD004654.
95. Kohlroser, J, Mathai, J, Reichheld, J, Banner, BF, Bonkovsky, HL, Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95 (2000), 272–276.
96. Mahaffey, KW, Hafley, G, Dickerson, S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J, 166, 2013, 240 249. e1.
97. Authors/Task Force Members, Ryden, L, Grant, PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
98. Loke, YK, Singh, S, Furberg, CD, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180 (2009), 32–39.
99. Lewis, JD, Habel, LA, Quesenberry, CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
100. Tuccori, M, Filion, KB, Yin, H, Yu, OH, Platt, RW, Azoulay, L, Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ, 352, 2016, i1541.
101. Nauck, MA, Meier, JJ, The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4 (2016), 525–536.
102. Garber, A, Henry, R, Ratner, R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
103. Trujillo, JM, Nuffer, W, Ellis, SL, GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 6 (2015), 19–28.
104. Zaccardi, F, Htike, ZZ, Webb, DR, Khunti, K, Davies, MJ, Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med 164 (2016), 102–113.
105. Butler, PC, Elashoff, M, Elashoff, R, Gale, EA, A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care 36 (2013), 2118–2125.
106. Eng, C, Kramer, CK, Zinman, B, Retnakaran, R, Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384 (2014), 2228–2234.
107. Heine, RJ, Van Gaal, LF, Johns, D, Mihm, MJ, Widel, MH, Brodows, RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (2005), 559–569.
108. Vasilakou, D, Karagiannis, T, Athanasiadou, E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
109. Nauck, MA, Del Prato, S, Meier, JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 (2011), 2015–2022.
110. Rosenstock, J, Jelaska, A, Wang, F, et al. Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Can J Diabetes, 37, 2013, S32.
111. Tahrani, AA, Barnett, AH, Bailey, CJ, SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1 (2013), 140–151.
112. Peters, AL, Buschur, EO, Buse, JB, Cohan, P, Diner, JC, Hirsch, IB, Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
113. Barnett, AH, Complementing insulin therapy to achieve glycemic control. Adv Ther 30 (2013), 557–576.
114. Davies, MJ, Gagliardino, JJ, Gray, LJ, Khunti, K, Mohan, V, Hughes, R, Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med 30 (2013), 512–524.
115. Holman, RR, Farmer, AJ, Davies, MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361 (2009), 1736–1747.
116. Weng, J, Li, Y, Xu, W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371 (2008), 1753–1760.
117. Horvath, K, Jeitler, K, Berghold, A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2, 2007 CD005613.
118. Monami, M, Marchionni, N, Mannucci, E, Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81 (2008), 184–189.
119. Swinnen, SG, Simon, AC, Holleman, F, Hoekstra, JB, Devries, JH, Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev, 7, 2011 CD006383.
120. Gururaj Setty, S, Crasto, W, Jarvis, J, Khunti, J, Davies, MJ, New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 92 (2016), 152–164.
121. Garber, AJ, King, AB, Del Prato, S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379 (2012), 1498–1507.
122. Steinstraesser, A, Schmidt, R, Bergmann, K, Dahmen, R, Becker, RH, Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 16 (2014), 873–876.
123. Crasto, W, Jarvis, J, Hackett, E, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 85 (2009), 219–222.
124. Mari, A, Rosenstock, J, Ma, X, Li, YG, Jackson, JA, Optimized human regular U-500 insulin treatment improves beta-cell function in severely insulin-resistant patients with long-standing type 2 diabetes and high insulin requirements. Endocr Pract 21 (2015), 1344–1352.
125. Zafar, A, Davies, M, Azhar, A, Khunti, K, Clinical inertia in management of T2DM. Prim Care Diabetes 4 (2010), 203–207.
126. Khunti, K, Wolden, ML, Thorsted, BL, Andersen, M, Davies, MJ, Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36 (2013), 3411–3417.
127. Khunti, K, Nikolajsen, A, Thorsted, BL, Andersen, M, Davies, MJ, Paul, SK, Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 8 (2016), 401–409.
128. Erickson, J, The cost of medication noncompliance. AAPPO J 3 (1993), 33–34 38–40.
129. Seaquist, ER, Anderson, J, Childs, B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
130. Cryer, PE, Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 63 (2014), 2188–2195.
131. Khunti, K, Alsifri, S, Aronson, R, et al. Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab 18 (2016), 907–915.
132. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care 38 (2015), 1583–1591.
133. Redelmeier, DA, Kenshole, AB, Ray, JG, Motor vehicle crashes in diabetic patients with tight glycemic control: a population-based case control analysis. PLoS Med, 6, 2009, e1000192.
134. American Diabetes Association. Diabetes and driving. Diabetes Care 37:suppl 1 (2014), S97–S103.
135. Sinclair, A, Dunning, T, Rodriguez-Manas, L, Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol 3 (2015), 275–285.
136. Greco, D, Pisciotta, M, Gambina, F, Maggio, F, Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 118 (2010), 215–219.
137. Lipska, KJ, Ross, JS, Miao, Y, Shah, ND, Lee, SJ, Steinman, MA, Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 175 (2015), 356–362.
138. Huang, ES, Laiteerapong, N, Liu, JY, John, PM, Moffet, HH, Karter, AJ, Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 174 (2014), 251–258.
139. Copeland, KC, Zeitler, P, Geffner, M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 96 (2011), 159–167.
140. Tamborlane, WV, Haymond, MW, Dunger, D, et al. Expanding treatment options for youth with type 2 diabetes: current problems and proposed solutions. A white paper From the NICHD Diabetes Working Group. Diabetes Care 39 (2016), 323–329.
141. Steven, S, Taylor, R, Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration type 2 diabetes. Diabet Med 32 (2015), 1149–1155.
142. Steven, S, Carey, PE, Small, PK, Taylor, R, Reversal of type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. Diabet Med 32 (2015), 47–53.
143. Xie, Z, Hao, H, Tong, C, et al. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells 34 (2016), 627–639.
144. Woo, VC, New insulins and new aspects in insulin delivery. Can J Diabetes 39 (2015), 335–343.
145. Finan, B, Yang, B, Ottaway, N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21 (2015), 27–36.
146. Gori, M, Gupta, DK, Claggett, B, et al. Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 39 (2016), 677–685.
147. Distiller, LA, Cranston, I, Mazze, R, First clinical experience with retrospective flash glucose monitoring (FGM) analysis in South Africa: characterizing glycemic control with ambulatory glucose profile. J Diabetes Sci Technol 10 (2016), 1294–1302.
148. Reznik, Y, Cohen, O, Aronson, R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 384 (2014), 1265–1272.
149. Cox, DJ, Taylor, AG, Moncrief, M, et al. Continuous glucose monitoring in the self-management of type 2 diabetes: a paradigm shift. Diabetes Care 9 (2016), e71–e73.
150. Kazierad, DJ, Bergman, A, Tan, B, et al. Effects of multiple ascending doses of the glucagon receptor antagonist, PF-06291874, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 18 (2016), 795–802.
151. Bailey, CJ, Tahrani, AA, Barnett, AH, Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol 4 (2016), 350–409.